Rapamune Off-Label Suit Prompts Congressional Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
House Oversight Committee is investigating allegations Wyeth promoted Rapamune for unapproved uses. Chairman Towns says he is concerned the drug was targeted to high-risk African-Americans; Pfizer says the drug is not contraindicated for this population.
You may also be interested in...
FDA Will Seek More Authority Over Manufacturing In Wake Of J&J Recalls
FDA will monitor more closely manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare
Pfizer Whistleblower Suit Alleges Sales Reps Had Targets For Rapamune Off-Label Uses
Former Wyeth sales reps also allege they were trained to avoid FDA personnel at medical meetings.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.